Abstract
The amyloid-β peptide (Aβ) is the major protein component of the characteristic cerebral plaques of Alzheimers disease (AD), and a large body of evidence supports a pathogenic role for this peptide. Thus, the proteases β- and γ-secretase that are responsible for carving Ab out of its precursor protein are considered prime targets for therapeutic design. β-Secretase is a membrane-anchored aspartyl protease of the pepsin family, while γ-secretase is much more complex. γ-Secretase requires presenilin, a multipass membrane protein that is the site of dozens of missense mutations that alter Ab formation and cause hereditary AD. Two conserved aspartates in presenilin are required for γ-secretase activity, and aspartyl protease transition-state analogue inhibitors of γ-secretase bind directly to presenilins, strong evidence that presenilin is the catalytic component of a novel membrane aspartyl protease. γ-Secretase appears to be a multi-component complex of integral membrane proteins, and so far presenilin and a single-pass membrane protein called nicastrin have been identified as members of this complex. A closely similar or identical protease activity is essential for a signaling pathway critical for embryogenesis and hematopoiesis, raising concerns about γ-secretase as a target. The development of potent and selective inhibitors with good pharmacokinetic properties may soon address these concerns.
Keywords: presenilin
Current Topics in Medicinal Chemistry
Title: γ-Secretase as a Target for Alzheimers Disease
Volume: 2 Issue: 4
Author(s): Michael S. Wolf
Affiliation:
Keywords: presenilin
Abstract: The amyloid-β peptide (Aβ) is the major protein component of the characteristic cerebral plaques of Alzheimers disease (AD), and a large body of evidence supports a pathogenic role for this peptide. Thus, the proteases β- and γ-secretase that are responsible for carving Ab out of its precursor protein are considered prime targets for therapeutic design. β-Secretase is a membrane-anchored aspartyl protease of the pepsin family, while γ-secretase is much more complex. γ-Secretase requires presenilin, a multipass membrane protein that is the site of dozens of missense mutations that alter Ab formation and cause hereditary AD. Two conserved aspartates in presenilin are required for γ-secretase activity, and aspartyl protease transition-state analogue inhibitors of γ-secretase bind directly to presenilins, strong evidence that presenilin is the catalytic component of a novel membrane aspartyl protease. γ-Secretase appears to be a multi-component complex of integral membrane proteins, and so far presenilin and a single-pass membrane protein called nicastrin have been identified as members of this complex. A closely similar or identical protease activity is essential for a signaling pathway critical for embryogenesis and hematopoiesis, raising concerns about γ-secretase as a target. The development of potent and selective inhibitors with good pharmacokinetic properties may soon address these concerns.
Export Options
About this article
Cite this article as:
Wolf S. Michael, γ-Secretase as a Target for Alzheimers Disease, Current Topics in Medicinal Chemistry 2002; 2 (4) . https://dx.doi.org/10.2174/1568026024607535
DOI https://dx.doi.org/10.2174/1568026024607535 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Frailty among HIV-1 Infected Adults under Antiretroviral Therapy in Indonesia
Current HIV Research Enzyme Kinetics for Clinically Relevant CYP Inhibition
Current Drug Metabolism Defining the Mechanism of Action of 4-Phenylbutyrate to Develop a Small-Molecule-Based Therapy for Alzheimers Disease
Current Medicinal Chemistry Proteins of the Esterase Family: Patents for Some Proteins in Search of Metabolic Functions
Recent Patents on Biomarkers PredCSF: An Integrated Feature-Based Approach for Predicting Conotoxin Superfamily
Protein & Peptide Letters Recent Advances Toward Improving the Bioavailability of Neuronal Nitric Oxide Synthase Inhibitors
Current Topics in Medicinal Chemistry State of the Art Management of Transfusion-Related Acute Lung Injury (TRALI)
Current Pharmaceutical Design Review of Structures Containing Fullerene-C60 for Delivery of Antibacterial Agents. Multitasking model for Computational Assessment of Safety Profiles
Current Bioinformatics Beyond Ketamine: New Approaches to the Development of Safer Antidepressants
Current Neuropharmacology Membrane Estrogen Receptors Acting in the Central Nervous System
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Salivary Aβ Secretion and Altered Oral Microbiome in Mouse Models of AD
Current Alzheimer Research Synaptic Correlates of Anterograde Amnesia and Intact Retrograde Memory in a Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Therapeutic Use of Antioxidants in Sepsis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Fumaric Acid and its Esters: An Emerging Treatment for Multiple Sclerosis
Current Neuropharmacology Role of NUCB2/nesfatin-1 as a Possible Biomarker
Current Pharmaceutical Design The Role of Iron Toxicity in Oxidative Stress-induced Cellular Degeneration in Down Syndrome: Protective Effects of Phenolic Antioxidants
Current Nutrition & Food Science The Role of Microglial Cell Subsets in Alzheimers Disease
Current Alzheimer Research Tumor Angiogenesis and VEGFR-2: Mechanism, Pathways and Current Biological Therapeutic Interventions
Current Drug Metabolism Dynamic Ventricular Repolarisation: From Physiology to Prognosis
Current Cardiology Reviews Mimicking Biogenic Silica Nanostructures Formation
Current Nanoscience